Research programme: cancer and autoimmune disorder therapeutics - Gliknik

Drug Profile

Research programme: cancer and autoimmune disorder therapeutics - Gliknik

Alternative Names: CD20 Stradobody; GB-4542; Rituximab biobetter - Gliknik; Stradobodies™; Stradomers™

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gliknik
  • Class
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 03 Mar 2016 Preclinical development is ongoing for Cancer and Autoimmune disorders in USA
  • 03 Oct 2011 Gliknik receives SBIR grant from the National Cancer Institute for the development of monoclonal antibody-like compounds in Cancer
  • 03 Oct 2011 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top